Prudent Man Investment Management Inc. Acquires Shares of 415 Johnson & Johnson (NYSE:JNJ)

Prudent Man Investment Management Inc. bought a new position in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 415 shares of the company’s stock, valued at approximately $60,000.

A number of other institutional investors have also made changes to their positions in the company. Principal Financial Group Inc. raised its position in shares of Johnson & Johnson by 10.5% during the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after purchasing an additional 329,473 shares during the period. United Bank increased its position in Johnson & Johnson by 5.6% in the third quarter. United Bank now owns 3,788 shares of the company’s stock worth $614,000 after buying an additional 202 shares during the period. Fred Alger Management LLC lifted its stake in Johnson & Johnson by 5.2% in the third quarter. Fred Alger Management LLC now owns 45,184 shares of the company’s stock valued at $7,323,000 after buying an additional 2,216 shares during the last quarter. Bellevue Group AG boosted its holdings in shares of Johnson & Johnson by 557.2% during the third quarter. Bellevue Group AG now owns 51,242 shares of the company’s stock valued at $8,304,000 after acquiring an additional 43,445 shares during the period. Finally, Plotkin Financial Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter worth about $488,000. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on JNJ. Bank of America upped their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 5th. Raymond James lowered their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Stifel Nicolaus lowered their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Finally, Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Price Performance

NYSE JNJ opened at $163.63 on Monday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The stock’s 50-day moving average price is $158.68 and its two-hundred day moving average price is $156.07. The company has a market cap of $394.32 billion, a PE ratio of 24.61, a PEG ratio of 2.56 and a beta of 0.47. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.03%. Johnson & Johnson’s payout ratio is presently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.